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Congenital central hypothyroidism (CCH) is a very rare disease. Alterations in pituitary development genes as well as mutations of 
immunoglobulin superfamily member 1 and transducin β-like protein 1 can result in CCH and multiple pituitary hormone deficiencies. 
However, mutations of the thyrotropin-releasing hormone receptor or thyroid-stimulating hormone-beta (TSHB) gene are responsible for 
isolated CCH. In this paper, we present the cases of two siblings with a novel mutation of TSHB. Direct sequencing of the coding regions 
and exon/intron boundaries of the TSHB gene revealed two homozygous nucleotides changes. One of them was c.40A>G (rs10776792) 
which is a very common variation that is also seen in healthy individuals, the other was c.94G>A at codon 32 of exon 2 which resulted 
in a change from glutamic acid to lysine (p.E32K). Both patients were homozygous and the parents were heterozygous.
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Introduction
Congenital central hypothyroidism (CCH) is a very rare 
disease associated with insufficient thyroid-stimulating 
hormone (TSH; also called thyrotropin) stimulation of a 
normally located thyroid gland. Alterations in pituitary 
development genes, such as PIT1, PROP1, HESX1, LHX3, 
LHX4, and SOX3 can result in CCH and multiple pituitary 
hormone deficiencies (1). Recently, mutations of the 
immunoglobulin super family member 1 (IGSF1) and 
transducin β-like protein 1 (TBL1X) genes have also been 
described as causes (2,3). IGSF1 is located on Xq 26.2 and 
its product may act as a signal transduction molecule in the 
hypophysis. Its precise physiological function is not known, 
but a deficiency of IGSF1 protein results in deficiencies 
of TSH and prolactin, pubertal delay and macroorchidism 
after adolescence (2). In cases with TBL1X gene mutations, 
hearing loss often accompanies central hypothyroidism (3).
Apart from these syndromic CCH causes, isolated CCH 
can be caused by mutations of the thyrotropin-releasing 
hormone (TRH) receptor, the least frequent one, or of TSH-
beta (TSHB) subunit genes. The TSHB gene is located on 
chromosome 1p13 and contains 3 exons. The second and 
third exons encode a mature protein of 112 amino acids (4).
In this paper, we report two siblings with congenital 
secondary hypothyroidism who were diagnosed at the ages 
of 16 and 20 with a new mutation in the TSHB-subunit gene.
Abstract
What is already known on this topic?
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This article presents a novel mutation of TSHB genes in 2 patients with CCH. 
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A 16-year-old girl was admitted to the hospital with a 20-
day history of persistent vaginal bleeding. The patient was 
born to non-consanguineous Turkish parents following an 
uneventful, full-term second pregnancy. Her past medical 
history revealed that she was developmentally delayed and 
that she had received L-thyroxine (T4) treatment for a short 
period at the age of 2; however, her parents did not continue 
the treatment. She had 3 siblings. Two of them are dizygotic 
twins whose ages are 5.26 years. The sister’s height is 100.2 
cm (Z-score; -1.22), weight 16.2 kg (Z-score; -1.22) and her 
brother’s height is 106.3 cm (Z-score; -1.22), weight 23 kg 
(Z-score; 1.26). Her oldest brother has short stature. 
The physical examination revealed a myxedematous face, 
thin hair, dry skin, a distended abdomen with an umbilical 
hernia, and psychomotor retardation. Her weight was 26 kg 
[standard deviation (SD) score -7.46], and she had a height 
of 96 cm (SD score -10.45), a body mass index of 28.26 kg/
m2, a blood pressure of 88/43 mmHg, and a pulse rate of 
117 bpm. Her thyroid gland was not palpable. Her breast 
development was consistent with Tanner stage 3, she had 
no pubic or axillary hair. 
The laboratory test results (Table 1A) showed that her 
creatinine phosphokinase, serum aspartate transaminase, 
alanine transaminase, triglyceride, and cholesterol levels 
were elevated. Her kidney function was within normal limits. 
The complete blood count revealed that she had severe 
anemia with a hemoglobin level of 5.6 g/dL associated with 
a deficiency of both iron and vitamin B12.
Her free T4 level was 0.05 ng/dL (0.8-2.2), and TSH level 
was 0.454 uIU/mL (0.51-4.30); prolactin (PRL) level was 15 
ng/mL (4.79-23.3). Her follicle-stimulating hormone level 
(FSH) was 6.10 mIU/mL (0.5-2.41), luteinizing hormone 
(LH) level was 12.64 mIU/mL (0.18-0.3), and estradiol level 
46.08 ng/mL (12.5-166). Insulin-like growth factor 1 level 
was 38.7 ng/mL (226-903). Radiological investigations 
revealed delayed bone age, epiphyseal dysgenesis,  and 
kyphoscoliosis (Figure 1). Ultrasonography of her pelvis 
showed follicles in both ovaries, a uterine length of 57 mm, 
and an endometrial thickness of 7 mm.
Serum samples were obtained at 0, 20, 40, and 60 
minutes after intravenous TRH (200 μg/m2) administration 
to evaluate her PRL and TSH responses (Table 1B). Her 
PRL response was normal, but there was no increase 
in TSH. Based on these physical findings and on the 
laboratory results which included low levels of free T4 
and TSH, a diagnosis of secondary hypothyroidism was 
made. The pituitary gland was found to be normal in a 
hypothalamus-pituitary magnetic resonance imaging. To 
check the integrity of the hypothalamic-pituitary-adrenal 
axis, a low-dose adrenocorticotropic hormone stimulation 
test was performed; her peak cortisol level was 21.38 µg/
dL. An echocardiogram was performed and it was normal. 
Usually, bradycardia accompanies hypothyroidism, but in 
our patient, tachycardia and hypotension were present due 
to severe anemia. L-T4 treatment was started. Her L-T4 dose 
was gradually increased from a quarter of the calculated 
dose to 100 µg/m2/day. Treatment with vitamin B12 and 
iron was also initiated for anemia.
Case 2
The 20-year-old brother of Case 1 was also affected (Figure 
2). He had coarse facial features, dry skin, cold extremities, 
and moderate intellectual disability. His weight was 46.4 kg 
(SD score -3), and he had a height of 133.4 cm (SD score -6), 
a blood pressure of 100/80 mmHg, and a pulse rate of 70 
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Table 1A. Anthropometric measurements and laboratory 
investigations in the two patients
Case 1 Case 2
Age at diagnosis (years) 16 20
Bone age (years) 3 15
Weight (kg)/Z-score 26/-7.46 47/-3
Height (cm)/ Z-score 96/-10.45 133.4/-6
ALT (IU/L) (<33) 44 25
AST (IU/L) (<32) 55 56
Triglyceride (mg/dL) (<200) 726 126




Ferritin (ng/mL) (20-200) 4.32 89
Vitamin B12 (pg/mL) (191-663) 181.7 275
Hemoglobin (g/dL) (12-18) 5.6 12.9
Mean corpuscular volume (fL)
(80-100)
94.4 87.3
CPK: creatinine phosphokinase, AST: aspartate transaminase, ALT: alanine 
transaminase 
Table 1B. Thyrotropin-releasing hormone stimulation 
test results of the index case
Time (min) 0’ 20’ 40’ 60’
TSH (uIU/mL) (0.6-4.84) 0.387 0.764 0.771 0.713
Prolactin (ng/mL) (4.79-23.3) 15 19 26 14
TSH: thyroid-stimulating hormone
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bpm. His thyroid gland was not palpable. Testicular volume 
was 20 mL bilaterally and his pubic hair was consistent with 
Tanner stage 4. His baseline free T4 level was 0.114 ng/dL 
(0.8-2.2), TSH level was 1.93 IU/mL (0.51-4.30), and PRL 
level 30 ng/mL (4.79-23.3). His FSH level was 2.35 mIU/
mL (1.5-12.4), LH level 3.98 mIU/mL (1.7-8.6), and total 
testosterone level was 5.81 ng/mL (2.8-8). His hemoglobin 
level was normal, and his cortisol level was 10.76 µg/dL. 
Insulin-like growth factor 1 level was 216 ng/mL (116-358). 
His bone age was consistent with age 15 years. Based on 
these physical findings and on the laboratory results (Table 
1A), a diagnosis of isolated secondary hypothyroidism was 
made, and L-T4 therapy was initiated with a low dose and 
titrated with free T4 values to maintain the serum free T4 
concentration in the upper 50 percent of the normal range. 
In both patients, euthyroid status was achieved after the 
first month of therapy. Lipid profile and liver function test 
abnormalities of the first proband normalized and the 
anemia improved.
Genetic Analyses
Genomic DNA was extracted from peripheral blood 
leucocytes of the patients and their family members using a 
commercially available DNA extraction kit (QuickGene DNA 
whole blood kit S, Japan). DNA quality control was checked 
using a spectrophotometer (Thermo Scientific NanoDrop 
2000, USA). Specific primers were designed to amplify 
all the coding regions and the exon/intron boundaries of 
the TSHB gene using a polimerase chain reaction (PCR). 
For exon II, the forward primer was 
5’-GGGATGGTACTGAAGTTTGGT-3’, and the reverse primer 
was 5’-AGATTTGGGAAATGAGGTTGTG- 3’; for exon III the 
forward primer was 5’-GGCTAAGCAATTCTTTCCCAGT-3’ and 
the reverse primer was 5’-GCTCTCTAACGCCTGTGTAGG-3’. 
ExPrime Taq Premix was used as the PCR master mix. The 
quality of the PCR reaction was analyzed using 2% agarose 
gel electrophoresis. An OMEGA bio-tek E.Z.N.A. Cycle 
Pure kit was used to purify the PCR products. The purified 
specific PCR products were then directly sequenced using a 
commercial kit according to the manufacturer’s instructions 
(GenomeLab DTCS-Quick Start Kit, USA; BECKMAN Coultur 
CEQ 8000 Genetic Analysis System, USA).
Direct sequencing of the coding regions and the exon/intron 
boundaries for the TSHB gene revealed 2 homozygous 
nucleotide changes. The first C.40A>G (rs10776792) is a 
Figure 2. Pedigree of the family
Figure 3. Homozygous c.94G>A
Figure 4. Heterozygous c.94G>A
Figure 1. Epiphyseal dysgenesis and kyphoscoliosis in case 1
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very common variation that can also be seen in healthy 
individuals, including the healthy members of the family of 
the two patients (the parents and twin siblings). The other 
nucleotide change was c.94G>A at codon 32 of exon 2, 
which results in a change of glutamic acid to lysine (p.E32K). 
For this novel mutation, both patients were homozygous 
and the parents were heterozygous (Figures 2, 3, 4). The 
PolyPhen 2 (score: 0.987), SIFT (score: 0), and Mutation 
Taster prediction tools (disease causing) all predicted that 
the mutation was pathogenic. 
Discussion
We herein report two siblings with a new mutation of the 
TSHB gene in a non-consanguineous Turkish family. 
The first mutation in TSHB was a single-base substitution 
in the 29th codon resulting in the replacement of glycine 
by arginine (G29R) (5). Since the first description of TSHB 
gene mutation, additional mutations have been reported 
including missense (C108Y, C105R, and G49R), non-
sense, frameshift (p.E32*, p.Q69*, p.C125Vfs*10, and 
p.F77Sfs*6), and splice-site (c.162G>A, c.1625G>A) 
mutations (1,5,6,7,8,9,10,11,12). The most commonly 
reported mutation is the C105Vfs114X mutation. This 
mutation is located on exon 3 of the TSHB gene, and it was 
first described in 1996 (10).
The first reported Turkish cases were two siblings who 
had a C-to-T transition at nucleotide 654 which led to the 
conversion of a glutamine into a premature stop codon in 
codon 49 (Q49X) (12). In 2004, the IVS2+5 G>A mutation 
resulting in isolated TSH deficiency was reported in 4 
children from two consanguineous Turkish families (13). 
More recently, a homozygous TSHB deletion was found in 
a 51-day-old male of Turkish descent who was diagnosed 
during a prolonged jaundice investigation (14).
The mutation in our patients was c.94G>A at codon 
32 of exon 2; it resulted in a change from glutamic acid 
to lysine (p.E32K). Another homozygous mutation at the 
same position (c.94G>T, p.E32*) was previously reported 
in 3 Greek children from two families (9). In silico analysis 
of c.94G>A revealed that this alteration was pathogenic. 
To the best of  our knowledge, the mutation detected in 
our patients has never been reported in central corneal 
thickness. Unfortunately, we could not perform functional 
analyses, but the in silico analyses were in agreement that 
the variant has a disease-causing effect.
TSH, LH, and FSH are pituitary glycoprotein hormones. All 
three are composed of an alpha-subunit and a beta-subunit 
coupled with non-covalent bonds. Their alpha-subunits are 
identical, but their beta-subunits are hormone-specific and 
confer biological specificity. TSHB  gene mutations cause 
alterations in the size or shape of the TSHB-subunit by affecting 
the beta-subunit’s seatbelt region or by changing the protein 
building blocks that are used to make the beta-subunit (1). 
The production or release of functional TSH from the pituitary 
gland is thus decreased. This TSH deficiency results in low 
hormone levels and leads to hypothyroidism. Consequently, 
TRH levels increase to stimulate both the production of TSH 
and PRL. There is no increase in TSH levels, because both 
alpha- and beta-subunits are needed to form intact TSH. On 
the other hand, serum alpha-subunit concentrations increase, 
a biochemical hallmark in TSHB gene mutations, and the PRL 
levels increase. For diagnostic purposes, in these patients, high 
serum alpha-subunit concentrations or a TRH stimulation test 
can be used to show isolated TSH deficiency and to indicate 
that the TRH receptor is intact based on an elevated PRL 
level (1). We performed a TRH stimulation test only for the 
index case, and the results were compatible with those for 
an isolated TSH deficiency. The elevated basal PRL levels and 
the very low TSH levels despite the severe hypothyroidism in 
the second case were also considered findings indicative of 
isolated TSH deficiency.
The clinical consequences of CCH are related to the severity 
and duration of thyroid hormone deprivation. The mutations 
probably have little impact on phenotype, and no genotype-
phenotype correlation has been reported. All of the reported 
cases showed clinical signs of hypothyroidism, such as 
prolonged jaundice, coarse facies, large fontanelles, dry 
skin, umbilical hernia, enlarged tongue, mental and motor 
retardation. Both patients were in their late teens and both 
showed all of the clinical and metabolic signs of severe 
hypothyroidism. They also both had severe motor and 
mental retardation. The index case had kyphoscoliosis in 
addition to a very short stature. The radiological appearance 
was compatible with epiphyseal dysgenesis which is a 
hallmark of long-standing untreated hypothyroidism (15). 
Hypothyroidism is treated with L-thyroxine, but measurement 
of serum TSH cannot be used as a guide to the adequacy 
of T4 replacement therapy in CCH. Serum TSH is always 
suppressed to <0.1 mU/L, so dosage should be titrated with 
free T4 value to maintain the serum free T4 concentration in 
the upper 50 percent of the normal range (16).
Congenital hypothyroidism is the most common preventable 
cause of mental retardation. Screening programs for 
newborns were developed to detect this preventable 
condition as early as possible. Screening by T4 and TSH 
is highly sensitive. However, TSH-based screening is more 
frequently used around the world even though it often 
leads to central hypothyroidism being overlooked (17). 
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Identification of a TSHB mutation would help in the genetic 
counseling and early diagnosis of siblings in affected 
families.
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